Skip to content

Serum Immunologic Markers Levels in During the Delivery

Dynamics of Serum Immunologic Markers Levels in During the Delivery and Possible Benefit for Obstetric Emergency Diagnostics

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03664999
Acronym
DIMDOED
Enrollment
57
Registered
2018-09-11
Start date
2018-09-08
Completion date
2019-06-30
Last updated
2019-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunologic Markers

Brief summary

This study aim to describe dynamics of immunologic markers C1 inhibitor, C3, C4 during the delivery in order to improve early diagnostics of obstetric emergencies, especially with immune etiology.

Detailed description

Our prospective observational study will explore the differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony). We will focus on women undergoing the Caesarean delivery. We will also measure D vitamin levels and ACE levels and search for some contexts.

Interventions

DIAGNOSTIC_TESTBlood sampling

differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony).

Sponsors

Brno University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
15 Years to 50 Years

Inclusion criteria

* Pregnant women undergoing the Caesarean delivery * Signed informed consent

Exclusion criteria

* Previous hepatitis or other hepatocyte damage

Design outcomes

Primary

MeasureTime frameDescription
Change in levels of total C1 inhibitor30 minutes before and 30 minutes after deliveryChenge in levels of total C1 inhibitor
Change in levels of CRP levels30 minutes before and 30 minutes after deliveryChange in levels of CRP levels
Change in levels of D vitamin levels30 minutes before and 30 minutes after deliveryChange in levels of D vitamin levels and it's relationship to pre-eclampsia
Change in levels of ACE levels30 minutes before and 30 minutes after deliveryChange in levels of ACE levels
Change of C1 inhibitor activity30 minutes before and 30 minutes after deliveryChange of C1 inhibitor activity
Change in levels of total C330 minutes before and 30 minutes after deliveryChange in levels of total C3
Change in levels of total C430 minutes before and 30 minutes after deliveryChange in levels of total C4

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026